Literature DB >> 8627012

Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease.

G Boivin1, S Chou, M R Quirk, A Erice, M C Jordan.   

Abstract

Cytomegalovirus (CMV) UL97 mutations associated with ganciclovir resistance at codons 460, 594, and 595 were detected by polymerase chain reaction (PCR) followed by restriction enzyme analysis in CMV blood isolates and directly in polymorphonuclear leukocyte (PMNL) DNA extracts of 4 subjects who died of progressive disseminated CMV disease due to ganciclovir-resistant CMV strains. The CMV DNA load was also serially determined in leukocyte fractions of these patients using a quantitative-competitive PCR assay. There was excellent concordance between specific UL97 mutations in blood culture isolates and those detected in PMNL fractions for all patients. Emergence of such UL97 mutations during ganciclovir therapy was associated with an increasing CMV DNA burden in leukocytes of the 2 patients with AIDS but not in the 2 subjects with chronic lymphocytic leukemia. Rapid molecular strategies, including detection of common CMV UL97 mutations and CMV DNA quantitation, can be used directly in leukocytes of immunocompromised subjects with CMV disease to monitor antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627012     DOI: 10.1093/infdis/173.3.523

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects.

Authors:  G Boivin; J Handfield; E Toma; G Murray; R Lalonde; V J Tevere; R Sun; M G Bergeron
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

3.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

Review 4.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System.

Authors:  G Boivin; J Handfield; G Murray; E Toma; R Lalonde; J G Lazar; M G Bergeron
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 6.  Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

Authors:  H Hebart; L Kanz; G Jahn; H Einsele
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 7.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 8.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

9.  Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS.

Authors:  Richard G Lalonde; Guy Boivin; Jean Deschênes; William G Hodge; J Jill Hopkins; Alex H Klein; Janette I Lindley; Peter Phillips; Stephen D Shafran; Sharon Walmsley
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

10.  Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.

Authors:  G Boivin; A Gaudreau; E Toma; R Lalonde; J P Routy; G Murray; J Handfield; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.